Isolation and characterization of acid and base degradation products in Atenolol and Hydrochlorothiazide and a validated selective stability-indicating HPLCUV method for their quantification

  • Indrani Bhattacharyya Dr B.C Roy College of Pharmacy and AHS, Dr. Meghnad Saha Sarani, Bidhan Nagar Pin-713206, Durgapur, West Bengal,
  • Souvik Basak Dr B.C Roy College of Pharmacy and AHS, Dr. Meghnad Saha Sarani, Bidhan Nagar Pin-713206, Durgapur, West Bengal,
  • Arindam Maity Dr B.C Roy College of Pharmacy and AHS, Dr. Meghnad Saha Sarani, Bidhan Nagar Pin-713206, Durgapur, West Bengal,
  • S. K Ghosh Department of Pharmaceutical Technology, Dibrugarh University, Assam,
Keywords: Stability indicating method, Atenolol, hydrochlorothiazide, Forced degradation


Atenolol ((RS)-2-{4-[2-Hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide) and Hydrochlorothiazide (6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide) are beta1 (?1) receptor blocker and diuretic drug respectively; however the combination dosage regime are used for cardiovascular therapy. Thus a forced degradation study was carried out upon this combination drug regime under acidic and basic environment in order to deconvolute the possible degradation product under specified stressed conditions. Under acidic conditions atenolol and hydrochlorothiazide were cleaved into 2-(4-(3-amino-2- oxopropoxy) phenyl) acetamide and 6-sulphamido benzothiazide. However, under basic conditions, the drugs were spliced into 2-(4-(2-hydroxypropoxy) phenyl) acetamide and 2-chloro 4-amino 1, 6-dihydro benzene sulphonamide respectively. The degradant peaks were elucidated by HPLC using C18 column with methanol: phosphate buffer (70:30 v/v) with a flow rate of 0.5ml/min (UV detection at 226nm).. For quantitative method validation, linearity was observed over product concentration range 2g/ml - 100 g/ml (r2 0.9992) with regression equation y=43432x. The products were first identified by LC-MS and further confirmed by FT-IR and 1H1 NMR. A specific and sensitive stability-indicating assay method for the simultaneous determination of the drugs, its process related impurities and degradation products was developed.


Download data is not yet available.


The British Pharmacopoeia 2007. The Stationery Office, London; Electronic version.

Martindale, Pharmaceutical Press, Edn 34, 2005, 865, 933, 947.

The Merck Index, Merck & Co., Inc., Edn 14, Whitehouse Station. NJ, 2006; 859, 4781, 5583.

Prasad CV, Parihar C, Sunil K, Parimoo P. Simultaneous determination of amiloride HCl, hydrochlorothiazide and atenolol in combined formulations by derivative spectroscopy. J Pharm Biomed Anal 1998; 17:877-84.

Sivakumar T, Venkatesan P, Manavalan R, Valliappan K. Development of a HPLC method for the simultaneous determination of Losartan potassium and Atenolol in tablets. Indian J Pharm Sci 2007; 69:154-57.

Parthiban C, Bhagavan RM, Sudhakar M. Simultaneous estimation and validation of Atenolol, hydrochlorothiazide and Losartank in dosage form by RP-HPLC method .Int J Pharm & Ind 2011; 1(4).

Nevin E. Spectrophotometric analysis of Hydrochlorothiazide and Valsartan. Analytical Letters 2002; 35:283-302.

Bhushan R, Deepak G, Shravan KS. Liquid chromatographic separation and UV determination of certain antihypertensive agents. Biomed Chromato 2005; 20:217-224.

Zaveri M, Khandhar A. Development and Validation of a RP-HPLC for the Simultaneous estimation of Atenolol and Hydrochlorothiazide in Pharmaceutical Dosage Forms. International Journal of Advances in Pharmaceutical Sciences 2010; 167-171.

Research Articles